CAR T cell therapy: newer approaches to counter resistance and cost

Heliyon

Alpana Sharma¹  Asgar Ali²  Santosh Kumar²  Rajesh Kumar Yadav²  Sadhana Sharma²  Chandramani Singh³  Basab Baghchi⁴  Sushmita Das⁵  Pritanjali Singh⁶ 

[1] Department of Biochemistry, All India Institute of Medical Sciences, Delhi, India;Department of Biochemistry, All India Institute of Medical Sciences, Patna, India;Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, India;Department of Medical Oncology/Haematology, All India Institute of Medical Sciences, Patna, India;Department of Microbiology, All India Institute of Medical Sciences, Patna, India;Department of Radiotherapy, All India Institute of Medical Sciences, Patna, India;

关键词: Immunotherapy;    CAR T cells;    Tumor mutation burden;    Epigenetics;    Combination therapy;    Affordable;   

DOI  :  

来源: DOAJ

【 摘 要 】

The genetically engineered Chimeric Antigen Receptor bearing T-cell (CAR T cell) therapy has been emerged as the new paradigm of cancer immunotherapy. However, recent studies have reported an increase in the number of relapsed haematological malignancies. This review provides newer insights into how the efficacy of CAR T cells might be increased by the application of new genome editing technologies, monitoring the complexity of tumor types and T cells sub-types. Next, tumor mutation burden along with tumormicroenvironment and epigenetic mechanisms of CAR T cell as well as tumor cell may play a vital role to tackle the cancer resistance mechanisms. These studies highlight the need to consider traditional cancer therapy in conjunction with CAR T cell therapy for relapsed or cases unresponsive to treatment. Of note, this therapy is highly expensive and requires multi-skill for successful implementation, which results in reduction of its accessibility/affordability to the patients. Here, we also propose a model for cost minimization of CAR T cell therapy by a collaboration of academia, hospitals and industry.

【 授权许可】

Unknown